48L Stock Overview
A commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Beyond Air, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.52 |
| 52 Week High | US$1.97 |
| 52 Week Low | US$0.23 |
| Beta | -0.18 |
| 11 Month Change | 80.07% |
| 3 Month Change | 43.06% |
| 1 Year Change | -63.66% |
| 33 Year Change | -95.94% |
| 5 Year Change | n/a |
| Change since IPO | -89.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| 48L | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 10.0% | 2.9% | 0.8% |
| 1Y | -63.7% | -4.7% | 8.6% |
Return vs Industry: 48L underperformed the German Medical Equipment industry which returned -5% over the past year.
Return vs Market: 48L underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| 48L volatility | |
|---|---|
| 48L Average Weekly Movement | 20.2% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 48L's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 48L's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 107 | Steve Lisi | www.beyondair.net |
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn.
Beyond Air, Inc. Fundamentals Summary
| 48L fundamental statistics | |
|---|---|
| Market cap | €37.62m |
| Earnings (TTM) | -€52.96m |
| Revenue (TTM) | €2.24m |
20.6x
P/S Ratio-0.9x
P/E RatioIs 48L overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 48L income statement (TTM) | |
|---|---|
| Revenue | US$2.34m |
| Cost of Revenue | US$4.63m |
| Gross Profit | -US$2.29m |
| Other Expenses | US$53.20m |
| Earnings | -US$55.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.77 |
| Gross Margin | -97.61% |
| Net Profit Margin | -2,369.17% |
| Debt/Equity Ratio | 53.3% |
How did 48L perform over the long term?
See historical performance and comparison